Free Trial

Belite Bio (BLTE) Competitors

Belite Bio logo
$60.12 +1.49 (+2.54%)
As of 07/8/2025 04:00 PM Eastern

BLTE vs. ELAN, RVMD, LEGN, GRFS, TGTX, NUVL, LNTH, TLX, AXSM, and AKRO

Should you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.

Belite Bio vs. Its Competitors

Elanco Animal Health (NYSE:ELAN) and Belite Bio (NASDAQ:BLTE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 0.9% of Elanco Animal Health shares are held by company insiders. Comparatively, 13.3% of Belite Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Elanco Animal Health has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500.

Elanco Animal Health has a net margin of 8.43% compared to Belite Bio's net margin of 0.00%. Elanco Animal Health's return on equity of 7.54% beat Belite Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Elanco Animal Health8.43% 7.54% 3.57%
Belite Bio N/A -32.07%-30.91%

Elanco Animal Health has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Elanco Animal Health$4.44B1.65$338M$0.7419.93
Belite BioN/AN/A-$36.14M-$1.36-44.21

Elanco Animal Health currently has a consensus price target of $15.33, indicating a potential upside of 3.95%. Belite Bio has a consensus price target of $96.67, indicating a potential upside of 60.79%. Given Belite Bio's stronger consensus rating and higher probable upside, analysts plainly believe Belite Bio is more favorable than Elanco Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Elanco Animal Health
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Belite Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Elanco Animal Health had 6 more articles in the media than Belite Bio. MarketBeat recorded 10 mentions for Elanco Animal Health and 4 mentions for Belite Bio. Elanco Animal Health's average media sentiment score of 0.43 beat Belite Bio's score of 0.39 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Elanco Animal Health
1 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Belite Bio
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Elanco Animal Health beats Belite Bio on 11 of the 14 factors compared between the two stocks.

Get Belite Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLTE vs. The Competition

MetricBelite BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.87B$2.87B$5.47B$8.95B
Dividend YieldN/A2.46%5.25%4.06%
P/E Ratio-44.2120.8027.0020.10
Price / SalesN/A286.27428.95120.24
Price / CashN/A41.1936.8257.86
Price / Book12.747.487.985.56
Net Income-$36.14M-$55.04M$3.16B$248.40M
7 Day Performance5.83%2.44%2.39%4.67%
1 Month Performance-2.08%1.90%2.18%6.64%
1 Year Performance22.20%4.35%33.82%21.31%

Belite Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BLTE
Belite Bio
2.4162 of 5 stars
$60.12
+2.5%
$96.67
+60.8%
+23.7%$1.87BN/A-44.2110High Trading Volume
ELAN
Elanco Animal Health
2.3486 of 5 stars
$14.29
flat
$15.17
+6.1%
+5.7%$7.10B$4.44B19.319,000
RVMD
Revolution Medicines
4.5646 of 5 stars
$36.79
-0.3%
$67.58
+83.7%
-7.9%$6.88B$11.58M-9.20250Positive News
LEGN
Legend Biotech
3.0571 of 5 stars
$35.49
+2.5%
$76.20
+114.7%
-20.9%$6.36B$627.24M-60.152,609Analyst Forecast
GRFS
Grifols
4.088 of 5 stars
$9.04
+2.0%
$10.30
+13.9%
+7.0%$6.09B$7.81B7.7323,822Analyst Upgrade
TGTX
TG Therapeutics
3.8984 of 5 stars
$35.99
-2.0%
$40.80
+13.4%
+82.1%$5.83B$329M149.96290Positive News
NUVL
Nuvalent
3.7498 of 5 stars
$76.30
-4.2%
$119.60
+56.7%
+8.9%$5.72BN/A-17.3840
LNTH
Lantheus
4.4181 of 5 stars
$81.86
+0.5%
$130.50
+59.4%
+4.6%$5.64B$1.53B23.26700
TLX
Telix Pharmaceuticals
N/A$16.07
+0.4%
$22.00
+36.9%
N/A$5.41B$516.72M0.00N/A
AXSM
Axsome Therapeutics
4.7367 of 5 stars
$104.39
+1.0%
$172.33
+65.1%
+29.6%$5.09B$385.69M-18.09380
AKRO
Akero Therapeutics
3.4454 of 5 stars
$53.36
-5.0%
$82.50
+54.6%
+127.0%$4.48BN/A-27.3630

Related Companies and Tools


This page (NASDAQ:BLTE) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners